<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liposomal amphotericin B: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liposomal amphotericin B: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Liposomal amphotericin B: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9499" href="/d/html/9499.html" rel="external">see "Liposomal amphotericin B: Drug information"</a> and <a class="drug drug_patient" data-topicid="11506" href="/d/html/11506.html" rel="external">see "Liposomal amphotericin B: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24673687"><span class="drugH1">Brand Names: US</span>
<ul>
<li>AmBisome</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865922"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AmBisome</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1045142"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antifungal Agent, Systemic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462370"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (eg, Abelcet, AmBisome) and amphotericin B deoxycholate (conventional amphotericin B).</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b2e0daa2-4d1c-4cd8-bcfc-ab13ebd61ad1">Candidiasis, CNS infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, CNS infection:</b> Preterm and term neonates: Limited data available: IV: 5 mg/kg/dose once daily. Doses as high as 7 mg/kg/dose once daily have been reported in treatment of non-CNS invasive candidiasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13680398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13680398'])">Ref</a></span>). Treat for ≥3 weeks and until all signs, symptoms, and cerebrospinal fluid and radiologic abnormalities resolve. May consider addition of flucytosine as salvage therapy in patients with inadequate clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd6e5847-c6b7-40e5-835b-9913ce34e6b3">Candidiasis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis,</b>
<b> invasive (non-CNS):</b> Preterm and term neonates: Limited data available: IV: 3 to 5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16354223','lexi-content-ref-26679628','lexi-content-ref-13680398','lexi-content-ref-18679151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16354223','lexi-content-ref-26679628','lexi-content-ref-13680398','lexi-content-ref-18679151'])">Ref</a></span>); doses as high as 7 mg/kg/dose once daily have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13680398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13680398'])">Ref</a></span>). Treat for ≥2 weeks after the first negative blood culture AND clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6cb02bb-5399-4d63-aff5-c4b202170424">Mucormycosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucormycosis, invasive:</b> Limited data available: <b>Note:</b> Prompt surgical debridement is often needed to achieve clinical cure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: IV: 5 to 10 mg/kg/dose once daily. Consider using higher end of dosing range for CNS disease. Total duration (including oral step-down therapy if possible) varies based on clinical and radiologic response and patient immune status; several months are often warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F134894"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (eg, Abelcet, AmBisome) and amphotericin B deoxycholate (conventional amphotericin B).</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b>
<i>Premedication:</i> To minimize infusion-related immediate reactions, may premedicate with acetaminophen, diphenhydramine, and/or hydrocortisone 30 to 60 minutes prior to administration. If the patient experiences rigors during the infusion, meperidine may be administered. Adequate hydration and preinfusion administration of NS may reduce the risk of nephrotoxicity during amphotericin B treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22581225','lexi-content-ref-25222303','lexi-content-ref-HIV.7','lexi-content-ref-HIV.12','lexi-content-ref-34716724','lexi-content-ref-AAP.2021','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22581225','lexi-content-ref-25222303','lexi-content-ref-HIV.7','lexi-content-ref-HIV.12','lexi-content-ref-34716724','lexi-content-ref-AAP.2021','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11922a6f-52e3-4d48-8959-25f730e3f929">Aspergillosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Invasive disease:</i> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily. Minimum duration of treatment is 6 to 12 weeks and depends on site of infection, extent of disease, and level/duration of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388','lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endocarditis</i>: Children and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90ff3b27-4e8f-490e-a6d4-4a1a6aab3eca">Blastomycosis, moderately severe to severe disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blastomycosis, moderately severe to severe disease:</b> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily for 1 to 2 weeks or until improvement, followed by oral itraconazole for a total of 12 months. For CNS disease, initial IV therapy at the higher end of the dosing range (5 mg/kg/dose) is recommended for 4 to 6 weeks, followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Invasive (alternative agent)</i>: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily. Duration of therapy should be individualized based on clinical response and presence of deep-tissue foci; candidemia should be treated for ≥14 days from the first negative blood culture and clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17503015','lexi-content-ref-HIV.12','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17503015','lexi-content-ref-HIV.12','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS</i>: Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily with or without flucytosine. Step down to azole therapy after initial response to treatment; overall duration is until all signs, symptoms, and cerebrospinal fluid/radiologic abnormalities have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endocarditis</i>: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine. Step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures. Total antifungal duration is ≥6 weeks after valve replacement surgery, with longer duration for perivalvular abscess, other complications, or a nonsurgical approach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Esophageal (alternative agent)</i>: Adolescents with HIV: IV: 3 to 4 mg/kg/dose once daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.7'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fb5d76c-3366-4cef-be06-02cc83aaddac">Coccidioidomycosis, severe, nonmeningeal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis, severe, nonmeningeal infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Patients with HIV:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV: 5 mg/kg/dose once daily; dose may be increased to as high as 10 mg/kg/dose once daily for life-threatening infection. Continue IV therapy until clinical improvement, then switch to an oral azole to complete ≥12 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.12']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.12'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV: 3 to 5 mg/kg/dose once daily until clinical improvement, then switch to an oral azole to complete ≥12 months of therapy. May consider initiating the oral azole in combination with the amphotericin B product and then continuing the oral azole when amphotericin B is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.7'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5e113884-4076-4d45-9925-fd1f21558240">Cryptococcosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcosis</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated cryptococcosis (non-CNS or severe pulmonary disease):</i> Infants, Children, and Adolescents: Induction therapy: IV: 3 to 5 mg/kg/dose once daily as part of an appropriate combination regimen for ≥2 weeks, followed by consolidation and maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.12','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.12','lexi-content-ref-20047480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Meningitis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients without HIV: Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily as part of an appropriate combination regimen for ≥2 weeks, followed by consolidation and maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900315','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900315','lexi-content-ref-20047480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: IV: 6 mg/kg/dose once daily as part of an appropriate combination regimen for ≥2 weeks, followed by consolidation and maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.12','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.12','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: IV: 3 to 4 mg/kg/dose once daily as part of an appropriate combination regimen for ≥2 weeks, followed by consolidation and maintenance therapy; doses up to 6 mg/kg/dose have been suggested for treatment of meningoencephalitis and may be considered for treatment failure or high fungal burden disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.7','lexi-content-ref-20047480','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.7','lexi-content-ref-20047480','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c793dec-5eab-4546-a35b-77e4454a2e01">Febrile neutropenia, empiric therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Febrile neutropenia, empiric therapy: </b>Infants, Children, and Adolescents: IV: 3 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22571507','lexi-content-ref-33811813','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22571507','lexi-content-ref-33811813','lexi-content-ref-27365388'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da0b3cae-9a59-4ae8-9ed2-c6aad13abf2e">Histoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histoplasmosis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Moderately severe to severe pulmonary or disseminated disease</i>: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily for 1 to 2 weeks (≥2 weeks for patients with HIV) and until clinical improvement, followed by oral itraconazole therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-Bradley.1','lexi-content-ref-HIV.7','lexi-content-ref-HIV.12','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-Bradley.1','lexi-content-ref-HIV.7','lexi-content-ref-HIV.12','lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS disease:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily for 4 to 6 weeks, followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HIV.7','lexi-content-ref-HIV.12','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HIV.7','lexi-content-ref-HIV.12','lexi-content-ref-17806045'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed727c2e-50ad-4916-9de0-8aa740ea0c6a">Leishmaniasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous infection</i>: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Patients without HIV: Infants, Children, and Adolescents: IV: 3 mg/kg/dose once daily on days 1 through 5, and then 3 mg/kg/dose on day 10 (for a total of 6 doses) <b>or</b> 3 mg/kg/dose once daily on days 1 through 7 (for a total of 7 doses). Cumulative dose administered should be 18 to 21 mg/kg to complete regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35810338','lexi-content-ref-27941143','lexi-content-ref-34716724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35810338','lexi-content-ref-27941143','lexi-content-ref-34716724'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV: Adolescents: IV: 2 to 4 mg/kg/dose once daily for 10 days (for a total of 10 doses) <b>or</b> an interrupted schedule of 4 mg/kg/dose on days 1 to 5 and on days 10, 17, 24, 31, and 38 (for a total of 10 doses) to achieve a <b>cumulative</b>
<b>dose</b> of 20 to 60 mg/kg to complete regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.7'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mucosal infection: </i>Limited data available: Infants, Children, and Adolescents: IV: ~3 mg/kg/dose once daily for 7 to 20 days (cumulative administered dose of ~20 to 60 mg/kg to complete regimen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Visceral infection:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Immunocompetent patients: Infants, Children, and Adolescents: IV: 3 mg/kg/dose once daily on days 1 through 5, and 3 mg/kg/dose on days 14 and 21; a repeat course may be given to patients who do not achieve parasitic clearance. Higher <b>cumulative doses</b> (ie, ≥40 mg/kg total) may be necessary if disease acquired in East Africa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Immunocompromised patients: Infants, Children, and Adolescents: IV: Initial: 4 mg/kg/dose once daily on days 1 through 5, and 4 mg/kg/dose on days 10, 17, 24, 31, 38 (for a total of 10 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: IV: Initial: 4 mg/kg/dose once daily on days 1 through 5, and 4 mg/kg/dose on days 10, 17, 24, 31, 38 (for a total of 10 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">Treatment: IV: 2 to 4 mg/kg/dose once daily <b>or</b> an interrupted schedule of 4 mg/kg/dose on days 1 through 5, and on days 10, 17, 24, 31, and 38. With either regimen, a <b>cumulative dose</b> of 20 to 60 mg/kg to complete regimen is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.7','lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.7','lexi-content-ref-27941143'])">Ref</a></span>). <b>Note: </b>Higher doses (eg, <b>cumulative dose</b> ≥40 mg/kg to complete regimen) and/or combination therapy may be required for patients with disease acquired in East Africa or Southeast Asia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143','lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Secondary prophylaxis (chronic maintenance therapy) for patients with HIV and high risk of visceral leishmaniasis relapse (eg, CD4 count &lt;200 cells/mm<sup>3</sup>): IV: 4 mg/kg/dose every 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.7'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6cb02bb-5399-4d63-aff5-c4b202170424">Mucormycosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucormycosis, invasive:</b> Limited data available: <b>Note:</b> Prompt surgical debridement is often needed to achieve clinical cure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 5 to 10 mg/kg/dose once daily. Consider using higher end of dosing range for CNS disease. Total duration (including oral step-down therapy if possible) varies based on clinical and radiologic response and patient immune status; several months are often warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3eb7406-2279-4fb2-ad39-e978257861e9">Sporotrichosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated, pulmonary, or osteoarticular disease:</i> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily, then switch to oral itraconazole after a favorable response is seen to complete ≥12 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-17968818','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-17968818','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Meningeal disease:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily for 4 to 6 weeks, followed by oral itraconazole to complete ≥12 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-17968818','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-17968818','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064823"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to severe impairment: Based on adult data, dosage adjustment is unlikely to be necessary because clearance by the kidney is low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11850268','lexi-content-ref-Nemecek.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11850268','lexi-content-ref-Nemecek.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent:</b> Unlikely to be dialyzed (lipophilic and highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11382716','lexi-content-ref-Nemecek.2019','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11382716','lexi-content-ref-Nemecek.2019','lexi-content-ref-manu.1'])">Ref</a></span>). Based on adult data, no dosage adjustment or supplemental dose necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-33179180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-33179180'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Unlikely to be significantly dialyzed: Based on adult data, no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12615870','lexi-content-ref-19397464','lexi-content-ref-33179180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12615870','lexi-content-ref-19397464','lexi-content-ref-33179180'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51064824"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F134884"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9499" href="/d/html/9499.html" rel="external">see "Liposomal amphotericin B: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Lipid-based amphotericin formulations (AmBisome) may be confused with conventional formulations (deoxycholate [Amphocin, Fungizone]) or with other lipid-based amphotericin formulations (amphotericin B lipid complex [Abelcet], amphotericin B cholesteryl sulfate complex [Amphotec]). Lipid-based and conventional formulations are <b>not </b>interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range: IV:</b> 3 to 6 mg/kg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Premedication: For patients who experience nonanaphylactic immediate infusion-related reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal anti-inflammatory agent ± diphenhydramine; <b>or</b> acetaminophen with diphenhydramine; <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e72c64d8-a342-4acc-a7d2-0c0fb8772cbd">Aspergillus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillus (systemic infection) (alternative therapy) (off-label dose):</b>
<b>IV:</b> 3 to 5 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>); doses up to 7.5 mg/kg once daily have been recommended for CNS infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>). Minimum duration of treatment is 6 to 12 weeks and depends on site of infection, extent of disease and level/duration of immunosuppression. <b>Note:</b> Guidelines recommend amphotericin B lipid formulations be considered for invasive aspergillosis only when triazoles, specifically voriconazole, are contraindicated or not tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Candidemia (non-neutropenic patients) (alternative agent): </i>
<b>IV:</b> 3 to 5 mg/kg once daily; may transition to fluconazole (usually after 5 to 7 days) in clinically stable patients, with fluconazole-susceptible isolates and negative repeat cultures. Total duration of antifungal therapy is at least 2 weeks <i>after</i> the documented clearance of <i>Candida</i> from the bloodstream and resolution of candidemia-associated symptoms in patients without metastatic complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Candidemia (neutropenic patients) (alternative agent): </i>
<b>IV: </b>3 to 5 mg/kg once daily; may transition to fluconazole during persistent neutropenia in clinically stable patients, with fluconazole-susceptible isolates and negative repeat cultures. Total duration of antifungal therapy is at least 2 weeks <i>after</i> the documented clearance of <i>Candida</i> from the bloodstream and resolution of neutropenia and candidemia-associated symptoms in patients without metastatic complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Central nervous system (eg, meningitis):</i>
<b>IV:</b> 5 mg/kg once daily (with or without oral flucytosine); step-down to fluconazole therapy is recommended after initial response to treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic disseminated (hepatosplenic)</i>:<b> IV:</b> 3 to 5 mg/kg once daily; after several weeks, transition to oral fluconazole in clinically stable, fluconazole-susceptible patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric therapy, suspected<i> invasive candidiasis </i> (non-neutropenic ICU patients) (alternative agent) (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Antifungal therapy is not routinely warranted for initial management of nonneutropenic patients with sepsis. Consider use for critically ill patients with unexplained fever or unexplained hypotension despite broad-spectrum antimicrobial therapy and risk factors for invasive candidiasis (eg, indwelling venous catheter, hemodialysis, trauma or burns, recent surgery, parenteral nutrition) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-34599691','lexi-content-ref-Vazquez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-34599691','lexi-content-ref-Vazquez.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 3 to 5 mg/kg once daily; treatment should continue for 14 days in patients with clinical improvement. Consider discontinuing after 4 to 5 days in patients with no clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endocarditis (native or prosthetic valve) or infected implantable cardiac devices (eg, pacemaker, ICD, VAD):</i>
<b>IV:</b> 3 to 5 mg/kg once daily (with or without flucytosine); for native or prosthetic valve endocarditis, therapy should continue for at least 6 weeks after valve replacement surgery (longer durations in patients with abscesses or other complications); for patients with implantable cardiac devices, therapy should continue for 4 to 6 weeks after surgery (4 for infections limited to generator pockets and at least 6 weeks for infections involving the wires). <b>Note:</b> May transition to fluconazole if patient clinically stable with fluconazole-susceptible isolates in whom <i>Candida</i> has cleared from the bloodstream; chronic or long-term suppression with fluconazole may be required (eg, prosthetic valve, valve-replacement not possible) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endophthalmitis (with or without vitritis) caused by fluconazole- or voriconazole-resistant isolates:</i>
<b>IV:</b> 3 to 5 mg/kg once daily (with or without flucytosine) for at least 4 to 6 weeks until examination indicates resolution; for patients with vitritis or with macular involvement (with or without vitritis), an intravitreal injection of voriconazole or amphotericin B deoxycholate is also recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Esophageal, refractory disease (alternative agent) (off-label use): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve use for patients who have inadequate response to or who are unable to take other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>3 mg/kg once daily. Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2','lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2','lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intra-abdominal candidiasis (alternative agent): </i>
<b>IV:</b> 3 to 5 mg/kg once daily; duration of therapy determined by clinical response and source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Osteomyelitis or septic arthritis due to Candida (alternative agent):</i>
<b> IV:</b> 3 to 5 mg/kg once daily for at least 2 weeks, followed by fluconazole for at least 4 weeks (septic arthritis) or for 6 to 12 months (osteomyelitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Suppurative thrombophlebitis:</i>
<b>IV:</b> 3 to 5 mg/kg once daily; continue for at least 2 weeks after candidemia has cleared; consider transition to fluconazole in clinically stable patients with a fluconazole-susceptible isolate who have responded to initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c886cb0-599e-4d09-b313-9fac581f96bd">Coccidioidomycosis in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis in patients with HIV (off-label use):</b>
<i>Non-CNS infection, severe (ie, diffuse pulmonary or severely ill with extrathoracic, disseminated disease): </i>
<b>IV:</b> 3 to 5 mg/kg once daily until clinical improvement, then initiate triazole therapy (eg, fluconazole or itraconazole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5e113884-4076-4d45-9925-fd1f21558240">Cryptococcosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcosis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated cryptococcosis (non-CNS or severe pulmonary disease): Induction therapy: </i>
<b>IV:</b> 3 to 4 mg/kg once daily with flucytosine (preferred) or fluconazole, or without a concomitant agent, for 2 weeks, followed by consolidation and maintenance therapy with fluconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900315','lexi-content-ref-HIV.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900315','lexi-content-ref-HIV.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Meningitis: Induction therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Resource-rich settings: <b>IV:</b> 3 to 4 mg/kg once daily with flucytosine (preferred) or fluconazole, or without a concomitant agent, for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900315','lexi-content-ref-HIV.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900315','lexi-content-ref-HIV.2'])">Ref</a></span>); doses up to 6 mg/kg/dose have been reported for treatment of meningoencephalitis and may be considered for treatment failure or high fungal burden disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20047480'])">Ref</a></span>). Induction therapy is followed by consolidation and maintenance therapy with fluconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900315','lexi-content-ref-HIV.2','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900315','lexi-content-ref-HIV.2','lexi-content-ref-20047480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Resource-limited settings:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> This regimen has only been studied in patients with HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35320642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35320642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 10 mg/kg as a single dose, in combination with 14 days of fluconazole and flucytosine. Induction therapy is followed by consolidation and maintenance therapy with fluconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35320642','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35320642','lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76ee1afc-c8f2-445b-9604-e46d2588759b">Fungal sinusitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fungal sinusitis:</b>
<b>IV:</b> Limited data in immunocompromised patients have shown efficacy with 3 to 10 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15815047','lexi-content-ref-15003897','lexi-content-ref-16918064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15815047','lexi-content-ref-15003897','lexi-content-ref-16918064'])">Ref</a></span>). <b>Note:</b> An azole antifungal is recommended if causative organism is <i>Aspergillus</i> spp or <i>Pseudallescheria boydii</i> (<i>Scedosporium</i> sp).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6562281-2fa6-4b61-86f8-13a170c56142">Fusariosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fusariosis, invasive (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>3 to 5 mg/kg once daily; duration of treatment is often prolonged and depends on site of infection, severity, immune status, and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-Nucci.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-Nucci.1'])">Ref</a></span>). <b>Note: </b>Some experts suggest combination antifungal therapy for patients with severe immunosuppression, severe disease, or increasing skin lesions or persistently positive blood cultures with monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nucci.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nucci.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CNS infection:</i> Initial: 5 mg/kg once daily in combination with voriconazole; dose escalation to 7.5 to 10 mg/kg once daily may be considered for insufficient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da0b3cae-9a59-4ae8-9ed2-c6aad13abf2e">Histoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histoplasmosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute pulmonary disease, moderately severe to severe:</i> Induction therapy: <b>IV:</b> 3 to 5 mg/kg once daily for 1 to 2 weeks, followed by itraconazole maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated disease, moderately severe to severe:</i> Induction therapy: <b>IV:</b> 3 mg/kg once daily for 1 to 2 weeks (patients without HIV) or at least 2 weeks (patients with HIV), followed by itraconazole maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2','lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Histoplasma meningitis:</i> Induction therapy:<b> IV:</b> 5 mg/kg once daily for 4 to 6 weeks, followed by itraconazole maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2','lexi-content-ref-17806045'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed727c2e-50ad-4916-9de0-8aa740ea0c6a">Leishmaniasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Cutaneous (off-label use):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients without HIV:</i>
<b>IV:</b> 3 mg/kg once daily on days 1 through 5, and then on day 10 <b>or </b>on days 1 through 7. Total dose administered should be 18 to 21 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with HIV:</i>
<b>IV:</b> 2 to 4 mg/kg once daily for 10 days <b>or</b> an interrupted schedule (eg, 4 mg/kg once daily on days 1 through 5, and then on days 10, 17, 24, 31, 38). Total dose administered should be 20 to 60 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Mucosal (off-label use):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients without HIV:</i>
<b>IV:</b> ~3 mg/kg once daily for a <b></b> cumulative total administered dose of ~20 to 60 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with HIV:</i>
<b>IV:</b> 2 to 4 mg/kg once daily for 10 days <b>or</b> an interrupted schedule (eg, 4 mg/kg once daily on days 1 through 5, and then on days 10, 17, 24, 31, 38). Total dose administered should be 20 to 60 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Visceral: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immunocompetent:</i>
<b>IV:</b> 3 mg/kg once daily on days 1 through 5, and 3 mg/kg once daily on days 14 and 21; a repeat course may be given in patients who do not achieve parasitic clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immunocompromised, including patients with HIV:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Treatment, monotherapy: <b>IV:</b> 2 to 4 mg/kg once daily <b>or</b> an interrupted schedule (eg, 4 mg/kg once daily on days 1 through 5, and then on days 10, 17, 24, 31, and 38). Total dose administered: 20 to 60 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Treatment, combination therapy: <b>Note:</b> For patients with HIV and visceral leishmaniasis acquired in East Africa or Southeast Asia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 5 mg/kg as a single dose on days 1, 3, 5, 7, 9, and 11 (total dose administered: 30 mg/kg) in combination with miltefosine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29799869','lexi-content-ref-35147680','lexi-content-ref-30653490','lexi-content-ref-26129756','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29799869','lexi-content-ref-35147680','lexi-content-ref-30653490','lexi-content-ref-26129756','lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Secondary prophylaxis (chronic maintenance therapy) for patients with HIV and high risk of visceral leishmaniasis relapse (eg, CD4 count &lt;200 cells/mm<sup>3</sup>): <b>IV:</b> 4 mg/kg once every 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2'])">Ref</a></span>). For patients with visceral leishmaniasis acquired in Southeast Asia, 3 to 5 mg/kg once every 3 to 4 weeks is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6519a1ec-6316-4b07-bee9-713696fdfed3">Meningitis, severe or in patients not improving with voriconazole monotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis (secondary to contaminated [eg, <i>Exserohilum rostratum]</i> steroid products), severe or in patients not improving with voriconazole monotherapy (off-label use)</b>
<b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2013','lexi-content-ref-23083312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2013','lexi-content-ref-23083312'])">Ref</a></span>):</b>
<b>IV:</b> 5 to 6 mg/kg once daily in combination with voriconazole for ≥3 months; a higher dose (7.5 mg/kg once daily) may be considered in patients who are not improving. <b>Note:</b> Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e2797af-46b9-47cf-be0c-b7200d6264f5">Mucormycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucormycosis (off-label use): IV:</b> 5 to 10 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664','lexi-content-ref-26316385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664','lexi-content-ref-26316385'])">Ref</a></span>). <b>Note:</b> 10 mg/kg once daily recommended for patients with CNS disease or solid organ transplant recipients. Treatment duration is typically weeks to months depending on response and host immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4088849b-2026-4ff7-9133-46527b2f5d43">Neutropenic fever, empirical antifungal therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, empirical antifungal therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Recommended for patients with persistent or recurrent fever after ≥4 days of antimicrobial therapy when the duration of neutropenia is expected to exceed 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094','lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>3 to 5 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388','lexi-content-ref-10072411','lexi-content-ref-11073745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388','lexi-content-ref-10072411','lexi-content-ref-11073745'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65656969-8b05-43d0-9f22-153af38a727d">Osteoarticular infection, severe or in patients with clinical instability</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarticular infection (secondary to contaminated [eg,</b>
<b>
<i>Exserohilum rostratum</i></b>
<b>] steroid products), severe or in patients with clinical instability (off-label use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2013','lexi-content-ref-23083312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2013','lexi-content-ref-23083312'])">Ref</a></span>): IV:</b> 5 mg/kg once daily in combination with voriconazole for ≥3 months. <b>Note: </b>Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6b7e66f-be22-4b1c-9703-113d514311f2">Talaromycosis in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Talaromycosis (formerly Penicillinosis) </b>
<b>in patients with HIV (off-label use):</b>
<b>IV:</b> 3 to 5 mg/kg once daily for 2 weeks, followed by oral itraconazole for 10 weeks, followed by chronic maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991911"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (clearance by the kidney is only 5% of total clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11850268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11850268'])">Ref</a></span>)) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nemecek.2019','lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nemecek.2019','lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (lipophilic and highly protein bound (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11382716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11382716'])">Ref</a></span>)): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-33179180','lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-33179180','lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (lipophilic and highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Unlikely to be significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12615870','lexi-content-ref-19397464','lexi-content-ref-33179180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12615870','lexi-content-ref-19397464','lexi-content-ref-33179180'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Unlikely to be significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989168"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). </p></div>
<div class="block arsc drugH1Div" id="F56809523"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Electrolyte abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B (liposomal) is associated with <b>hypocalcemia</b>, <b>hypokalemia</b>, <b>hypomagnesemia</b>, and <b>hyponatremia</b>. Depletion of these electrolytes can predispose the patient to severe adverse reactions (<b>asthenia</b>, <b>rhabdomyolysis</b>, and <b>cardiac arrhythmias</b>). Compared with conventional amphotericin, liposomal amphotericin is associated with fewer cases of hypokalemia and hypomagnesemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10072411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10072411'])">Ref</a></span>). No significant differences in frequency of hypokalemia have been observed between patients who received liposomal amphotericin and amphotericin B lipid complex at a dose of 5 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11073745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11073745'])">Ref</a></span>). Electrolyte abnormalities may continue for weeks after dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10669191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10669191'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Alters cell membrane permeability leading to intracellular leakage and various tubular defects, causing electrolyte abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7579079','lexi-content-ref-10669191','lexi-content-ref-11073745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7579079','lexi-content-ref-10669191','lexi-content-ref-11073745'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; in one study, hypokalemia occurred with a median onset of 10 days (range: 3 to 54 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28945677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28945677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline albumin level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24669255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24669255'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline electrolyte levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24669255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24669255'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of hypokalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24669255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24669255'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B (liposomal) is associated with a variety of hypersensitivity reactions, including immediate (eg, <b>infusion-related reaction, anaphylaxis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8566990','lexi-content-ref-7915365','lexi-content-ref-9734666','lexi-content-ref-27743834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8566990','lexi-content-ref-7915365','lexi-content-ref-9734666','lexi-content-ref-27743834'])">Ref</a></span>) and <b>type IV hypersensitivity reactions</b>, ranging from <b>skin rash</b>, with or without accompanying symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10423056','lexi-content-ref-21976565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10423056','lexi-content-ref-21976565'])">Ref</a></span>) to <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26420570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26420570'])">Ref</a></span>). Acute infusion-related reactions can include fever, chills or rigors, dyspnea, hypotension, tachycardia, hypertension, hypoxia, and chest pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23719882','lexi-content-ref-23166189','lexi-content-ref-12746764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23719882','lexi-content-ref-23166189','lexi-content-ref-12746764'])">Ref</a></span>); symptoms generally resolve after discontinuation of the infusion and administration of an antihistamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9758315','lexi-content-ref-12746764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9758315','lexi-content-ref-12746764'])">Ref</a></span>). Based on symptom presentation, it is difficult to differentiate between anaphylaxis and infusion-related reactions, although infusion-related reactions generally occur with the first dose without previous exposure to amphotericin B compounds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10451192','lexi-content-ref-25139411','lexi-content-ref-29136631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10451192','lexi-content-ref-25139411','lexi-content-ref-29136631'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Dose-related, non-immunologic. Possibly related to liposomal complement activation leading to development of complement activation-related pseudoallergy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34325715','lexi-content-ref-23931455','lexi-content-ref-33549818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34325715','lexi-content-ref-23931455','lexi-content-ref-33549818'])">Ref</a></span>) or to release of IL-1 beta, TNF-alpha, and prostaglandin E<sub>2</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14692429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14692429'])">Ref</a></span>). Liposome rather than the amphotericin B component is likely the key factor in inducing immediate reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34325715','lexi-content-ref-7915365','lexi-content-ref-9734666','lexi-content-ref-12196074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34325715','lexi-content-ref-7915365','lexi-content-ref-9734666','lexi-content-ref-12196074'])">Ref</a></span>). Although there are numerous case reports of anaphylaxis related to liposomal amphotericin B in the literature, none have shown an IgE-mechanism; most of the reported reactions are likely infusion-related reactions.</p>
<p style="text-indent:-2em;margin-left:6em;">Type IV hypersensitivity reactions: Non–dose-related, immunologic. Maculopapular eruptions and DRESS are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infusion-related reactions: Rapid; can occur with the initial dose, often within the first 5 minutes of infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10451192','lexi-content-ref-12746764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10451192','lexi-content-ref-12746764'])">Ref</a></span>); tolerance to infusion-related reactions usually develops during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12746764','lexi-content-ref-11428998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12746764','lexi-content-ref-11428998'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Type IV hypersensitivity reactions: Varied; maculopapular rash usually occurs 5 to 7 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26553194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26553194'])">Ref</a></span>) and DRESS usually occurs 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-26420570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-26420570'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Although slowing the rate of infusion reduces risk of developing infusion-related events for conventional amphotericin B deoxycholate, this strategy may not be necessary for liposomal amphotericin B (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12746764','lexi-content-ref-11428998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12746764','lexi-content-ref-11428998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Decreased risk of infusion-related adverse reactions with liposomal amphotericin B compared to other amphotericin B formulations, including conventional amphotericin and amphotericin B lipid complex, in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16622909','lexi-content-ref-11428998','lexi-content-ref-23774005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16622909','lexi-content-ref-11428998','lexi-content-ref-23774005'])">Ref</a></span>) but not in children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29352486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29352486'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Most patients who develop a severe infusion reaction to liposomal or amphotericin can tolerate alternative formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23719882','lexi-content-ref-23166189','lexi-content-ref-9758315','lexi-content-ref-7915365','lexi-content-ref-27365388','lexi-content-ref-12196074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23719882','lexi-content-ref-23166189','lexi-content-ref-9758315','lexi-content-ref-7915365','lexi-content-ref-27365388','lexi-content-ref-12196074'])">Ref</a></span>); although, some patients develop reactions on multiple lipid formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11261528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11261528'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clinical manifestations of amphotericin B (liposomal) <b>nephrotoxicity </b>may range from <b>increased serum creatinine </b>to <b>acute kidney injury </b>(occasionally leading to chronic kidney disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33239137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33239137'])">Ref</a></span>). Compared with amphotericin deoxycholate, liposomal amphotericin is associated with fewer nephrotoxic events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9792309','lexi-content-ref-22491505','lexi-content-ref-9332329','lexi-content-ref-10072411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9792309','lexi-content-ref-22491505','lexi-content-ref-9332329','lexi-content-ref-10072411'])">Ref</a></span>). Differences between amphotericin B lipid complex and liposomal amphotericin are unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11560200','lexi-content-ref-20616663','lexi-content-ref-11073745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11560200','lexi-content-ref-20616663','lexi-content-ref-11073745'])">Ref</a></span>). Liposomal amphotericin nephrotoxicity is considered reversible, but cases of persistent damage have been observed. About 30% of patients with liposomal amphotericin-associated nephrotoxicity will have complete renal recovery within 10 days of onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30809394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30809394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; may be related to maximum daily dose and/or cumulative dose. Amphotericin alters cell membrane permeability, causing alterations in tubular and vascular smooth muscle cell function; decreased renal blood flow results in reduced glomerular filtration rate and direct renal tubular toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11576359','lexi-content-ref-9332329','lexi-content-ref-7579079']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11576359','lexi-content-ref-9332329','lexi-content-ref-7579079'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; duration of therapy prior to development of nephrotoxicity typically ranges from 3 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9332329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9332329'])">Ref</a></span>); median duration to onset ~3 to 4 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30809394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30809394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher daily dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11576359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11576359'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11576359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11576359'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline albumin level and albumin supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33239137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33239137'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent nephrotoxic drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11576359','lexi-content-ref-9332329','lexi-content-ref-26014956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11576359','lexi-content-ref-9332329','lexi-content-ref-26014956'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher weight and baseline body surface area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33239137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33239137'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26014956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26014956'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F134859"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (8% to 12%), edema (12% to 14%), hypertension (8% to 20%), hypotension (7% to 14%), peripheral edema (15%), tachycardia (9% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (11%), skin rash (5% to 25%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 1</a>)</span><span class="table-link" style="display:none;">Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Amphotericin B (Liposomal): Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">343</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">344</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (8% to 23%), hypervolemia (8% to 12%), hypocalcemia (5% to 18%)<span class="lexi-table-link-container"> (<a aria-label="Hypocalcemia table link" class="lexi-table-link" data-table-id="lexi-content-hypocalcemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypocalcemia')">table 2</a>)</span><span class="table-link" style="display:none;">Hypocalcemia</span>, hypokalemia (31% to 51%)<span class="lexi-table-link-container"> (<a aria-label="Hypokalemia table link" class="lexi-table-link" data-table-id="lexi-content-hypokalemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypokalemia')">table 3</a>)</span><span class="table-link" style="display:none;">Hypokalemia</span>, hypomagnesemia (15% to 49%)<span class="lexi-table-link-container"> (<a aria-label="Hypomagnesemia table link" class="lexi-table-link" data-table-id="lexi-content-hypomagnesemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypomagnesemia')">table 4</a>)</span><span class="table-link" style="display:none;">Hypomagnesemia</span>, hyponatremia (9% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Hyponatremia table link" class="lexi-table-link" data-table-id="lexi-content-hyponatremia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyponatremia')">table 5</a>)</span><span class="table-link" style="display:none;">Hyponatremia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypocalcemia" frame="border" id="lexi-content-hypocalcemia" rules="all">
<caption style="text-align:center;">
<b>Amphotericin B (Liposomal): Adverse Reaction: Hypocalcemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">343</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">344</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypokalemia" frame="border" id="lexi-content-hypokalemia" rules="all">
<caption style="text-align:center;">
<b>Amphotericin B (Liposomal): Adverse Reaction: Hypokalemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">343</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">344</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypomagnesemia" frame="border" id="lexi-content-hypomagnesemia" rules="all">
<caption style="text-align:center;">
<b>Amphotericin B (Liposomal): Adverse Reaction: Hypomagnesemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">49%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">343</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">344</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyponatremia" frame="border" id="lexi-content-hyponatremia" rules="all">
<caption style="text-align:center;">
<b>Amphotericin B (Liposomal): Adverse Reaction: Hyponatremia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Amphotericin B Deoxycholate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B Deoxycholate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (7% to 20%), anorexia (10% to 14%), constipation (15%), diarrhea (11% to 30%), nausea (16% to 40%), vomiting (11% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (27% to 48%), leukopenia (15% to 17%), thrombocytopenia (6% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (9% to 18%), increased serum alanine aminotransferase (15%), increased serum alkaline phosphatase (7% to 22%), increased serum aspartate aminotransferase (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (≤24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized phlebitis (9% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (7% to 14%), asthenia (6% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Asthenia table link" class="lexi-table-link" data-table-id="lexi-content-asthenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-asthenia')">table 6</a>)</span><span class="table-link" style="display:none;">Asthenia</span>, chills (≤48%), confusion (9% to 13%), headache (9% to 20%), insomnia (17% to 22%), pain (14%), rigors (≤48%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Asthenia" frame="border" id="lexi-content-asthenia" rules="all">
<caption style="text-align:center;">
<b>Amphotericin B (Liposomal): Adverse Reaction: Asthenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">343</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">344</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (7% to 21%), increased serum creatinine (14% to 47%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Creatinine table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-creatinine" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-creatinine')">table 7</a>)</span><span class="table-link" style="display:none;">Increased Serum Creatinine</span>, nephrotoxicity (19%)<span class="lexi-table-link-container"> (<a aria-label="Nephrotoxicity table link" class="lexi-table-link" data-table-id="lexi-content-nephrotoxicity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nephrotoxicity')">table 8</a>)</span><span class="table-link" style="display:none;">Nephrotoxicity</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Creatinine" frame="border" id="lexi-content-increased-serum-creatinine" rules="all">
<caption style="text-align:center;">
<b>Amphotericin B (Liposomal): Adverse Reaction: Increased Serum Creatinine</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">47%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 × baseline serum creatinine; comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 × baseline serum creatinine; comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 × baseline serum creatinine; comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 × baseline serum creatinine; comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cryptococcal meningitis in patients with HIV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">87</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 × baseline serum creatinine; comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">63%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 × baseline serum creatinine; comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">63%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 × baseline serum creatinine; comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">343</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">344</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B deoxycholate</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">49%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">49%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 × baseline serum creatinine; comparator: Amphotericin B lipid complex</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg/kg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 × baseline serum creatinine; comparator: Amphotericin B lipid complex</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nephrotoxicity" frame="border" id="lexi-content-nephrotoxicity" rules="all">
<caption style="text-align:center;">
<b>Amphotericin B (Liposomal): Adverse Reaction: Nephrotoxicity</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Amphotericin B Deoxycholate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B [Liposomal])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Amphotericin B Deoxycholate)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fungal infection, empiric therapy in febrile neutropenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">343</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">344</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (2% to 18%), dyspnea (18% to 23%), epistaxis (9% to 15%), pleural effusion (13%), rhinitis (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (2% to 10%), bradycardia (2% to 10%), cardiac arrhythmia (2% to 10%), cardiomegaly (2% to 10%), flushing (2% to 10%), heart valve disease (2% to 10%), orthostatic hypotension (2% to 10%), vascular disease (2% to 10%), vasodilation (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (2% to 10%), cellulitis (2% to 10%), dermal ulcer (2% to 10%), diaphoresis (7%), maculopapular rash (2% to 10%), skin discoloration (2% to 10%), urticaria (2% to 10%), vesiculobullous dermatitis (2% to 10%), xeroderma (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis (2% to 10%), hyperchloremia (2% to 10%), hyperkalemia (2% to 10%), hypermagnesemia (2% to 10%), hypernatremia (4%), hyperphosphatemia (2% to 10%), hypophosphatemia (2% to 10%), increased lactate dehydrogenase (2% to 10%), increased nonprotein nitrogen (2% to 10%), respiratory alkalosis (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Aphthous stomatitis (2% to 10%), dyspepsia (2% to 10%), dysphagia (2% to 10%), enlargement of abdomen (2% to 10%), eructation (2% to 10%), fecal incontinence (2% to 10%), flatulence (2% to 10%), gastrointestinal hemorrhage (10%), gingival hemorrhage (2% to 10%), hematemesis (2% to 10%), hemorrhoids (2% to 10%), hiccups (2% to 10%), increased serum amylase (2% to 10%), intestinal obstruction (2% to 10%), oral hemorrhage (2% to 10%), rectal disease (2% to 10%), stomatitis (2% to 10%), xerostomia (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (2% to 10%), toxic nephrosis (2% to 10%), urinary incontinence (2% to 10%), vaginal hemorrhage (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (2% to 10%), decreased prothrombin time (2% to 10%), disorder of hemostatic components of blood (2% to 10%), hemophthalmos (2% to 10%), hemorrhage (2% to 10%), hypoproteinemia (2% to 10%), petechia (2% to 10%), prolonged prothrombin time (2% to 10%), purpuric disease (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (2% to 10%), hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease) (2% to 10%), hepatomegaly (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (2% to 10%), hypersensitivity reaction (2% to 10%), type IV hypersensitivity reaction (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (2% to 10%), agitation (2% to 10%), coma (2% to 10%), depression (2% to 10%), dizziness (7% to 9%), drowsiness (2% to 10%), dysesthesia (2% to 10%), dystonia (2% to 10%), hallucination (2% to 10%), malaise (2% to 10%), nervousness (2% to 10%), paresthesia (2% to 10%), seizure (2% to 10%), tremor (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (2% to 10%), myalgia (2% to 10%), neck pain (2% to 10%), ostealgia (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (2% to 10%), dry eye syndrome (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (2% to 10%), renal failure syndrome (2% to 10%), renal function abnormality (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (2% to 10%), atelectasis (2% to 10%), dry nose (2% to 10%), flu-like symptoms (2% to 10%), hemoptysis (2% to 10%), hyperventilation (2% to 10%), hypoxia (6% to 8%), pharyngitis (2% to 10%), pneumonia (2% to 10%), pulmonary edema (2% to 10%), respiratory failure (2% to 10%), respiratory insufficiency (2% to 10%), sinusitis (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hemorrhagic cystitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Bates 1995, Laing 1994, Schenider 1998), angioedema (Nath 2014), drug reaction with eosinophilia and systemic symptoms (Hagihara 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Marking 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, cyanosis, hypoventilation</p></div>
<div class="block coi drugH1Div" id="F134872"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to amphotericin B deoxycholate or any component of the formulation </p></div>
<div class="block war drugH1Div" id="F134856"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Leukocyte transfusions: Acute pulmonary toxicity has been reported in patients receiving simultaneous leukocyte transfusions and amphotericin B.</p></div>
<div class="block foc drugH1Div" id="F24673688"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AmBisome: 50 mg (1 ea) [contains cholesterol, distearoyl phosphatidylglycerol, hydrogenated soy phosphatidylcholine, sodium succinate hexahydrate, sucrose, tocopherol, dl-alpha (vit e)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F134852"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322989"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (AmBisome Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $370.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Amphotericin B Liposome Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $305.69 - $305.70</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865923"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AmBisome: 50 mg (1 ea) [contains cholesterol, distearoyl phosphatidylglycerol, hydrogenated soy phosphatidylcholine, sodium succinate hexahydrate, sucrose, tocopherol, dl-alpha (vit e)]</p></div>
<div class="block adip drugH1Div" id="F53565314"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">The lipid portion of amphotericin B (liposomal) formulation contains 0.27 kcal per 5 mg; for patients receiving parenteral nutrition, adjustment to the amount of lipids may be necessary (Sacks 1997).</p></div>
<div class="block admp drugH1Div" id="F52612234"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">To minimize infusion-related immediate reactions, may premedicate with acetaminophen, diphenhydramine, and/or hydrocortisone 30 to 60 minutes prior to administration. If the patient experiences rigors during the infusion, meperidine may be administered. Adequate hydration and preinfusion administration of NS may reduce the risk of nephrotoxicity during amphotericin B treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22581225','lexi-content-ref-25222303','lexi-content-ref-HIV.7','lexi-content-ref-HIV.12','lexi-content-ref-34716724','lexi-content-ref-AAP.2021','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22581225','lexi-content-ref-25222303','lexi-content-ref-HIV.7','lexi-content-ref-HIV.12','lexi-content-ref-34716724','lexi-content-ref-AAP.2021','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: An in-line filter (≥1 micron) may be used. Flush line with D5W prior to infusion; infuse over 2 hours; if infusion is well-tolerated, infusion time may be reduced to 1 hour. If the patient experiences discomfort during infusion, the duration of infusion may be increased.</p></div>
<div class="block adm drugH1Div" id="F134869"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer via intravenous infusion, over a period of approximately 2 hours. Infusion time may be reduced to approximately 1 hour in patients in whom the treatment is well-tolerated. If the patient experiences discomfort during infusion, the duration of infusion may be increased. Existing intravenous line should be flushed with D<sub>5</sub>W before and after infusion (if not feasible, administer through a separate line). An in-line membrane filter (not less than 1 micron) may be used.</p>
<p style="text-indent:0em;margin-top:2em;">For a patient who experiences chills, fever, hypotension, nausea, or other nonanaphylactic immediate infusion-related reactions, premedicate with the following drugs, 30 to 60 minutes prior to drug administration: A nonsteroidal (eg, ibuprofen, choline magnesium trisalicylate) ± diphenhydramine <b>or </b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>
<p style="text-indent:0em;margin-top:2em;">Preinfusion administration of NS 500 to 1,000 mL IV appears to reduce the risk of nephrotoxicity during amphotericin B treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HIV.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HIV.2'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F134878"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;text-align:justify;display:inline">Store intact vials at ≤25°C (≤77°F). Reconstituted vials are stable at 2°C to 8°C (36°F to 46°F) for 24 hours. Do not freeze. Begin infusion within 6 hours of dilution with D<sub>5</sub>W. Extended storage information may be available; contact product manufacturer to obtain current recommendations.</p></div>
<div class="block usep drugH1Div" id="F53565418"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Empirical therapy for presumed fungal infection in febrile, neutropenic patients; treatment of patients with <i>Aspergillus</i> species, <i>Candida</i> species, and/or <i>Cryptococcus</i> species infections refractory to amphotericin B deoxycholate (conventional amphotericin), or in patients for whom renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate; treatment of cryptococcal meningitis in patients with HIV; treatment of visceral leishmaniasis (all indications: FDA approved in ages ≥1 month and adults); has also been used for treatment of blastomycosis, histoplasmosis infection, coccidioidomycosis, mucormycosis, and sporotrichosis<i>.</i></p></div>
<div class="block mst drugH1Div" id="F134910"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">AmBisome may be confused with Ambisolm, Ambisom</p>
<p style="text-indent:2em;">Amphotericin B liposomal may be confused with amphotericin B</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lipid-based amphotericin formulations (AmBisome) may be confused with conventional formulations (Amphocin, Fungizone) or with other lipid-based amphotericin formulations (Abelcet, Amphotec)</p>
<p style="text-indent:-2em;margin-left:4em;">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298746"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F134861"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. Amphotericin B may enhance the neurotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: Amphotericin B may enhance the hypotensive effect of Arsenic Trioxide. Amphotericin B may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as amphotericin B.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate.  Management: Avoid coadministration of colistimethate and amphotericin B whenever possible due to the potential for additive or synergistic nephrotoxicity. If coadministration cannot be avoided, closely monitor renal function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Amphotericin B may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Amphotericin B may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. Amphotericin B may increase the serum concentration of Flucytosine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Amphotericin B may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F14637213"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">If on parenteral nutrition, may need to adjust the amount of lipid infused. The lipid portion of amphotericin B (liposomal) formulation contains 0.27 kcal per 5 mg (Sacks 1997).</p></div>
<div class="block pri drugH1Div" id="F6866584"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women; refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmis 2015).</p></div>
<div class="block mopp drugH1Div" id="F53565421"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BUN, serum creatinine, ins &amp; outs, liver function tests, serum electrolytes (particularly magnesium and potassium), CBC, vital signs; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes) and infusion-related reactions.</p></div>
<div class="block pha drugH1Div" id="F134855"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman 1992).</p></div>
<div class="block phk drugH1Div" id="F134871"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Exhibits nonlinear kinetics (greater than proportional increase in serum concentration with an increase in dose)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.1 to 0.16 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 7 to 10 hours (following a single 24-hour dosing interval); Terminal half life: 100 to 153 hours (following multiple dosing up to 49 days)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29799869">
<a name="29799869"></a>Abongomera C, Diro E, de Lima Pereira A, et al. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral Leishmaniasis in HIV co-infected patients in Ethiopia: a retrospective cohort study. <i>PLoS Negl Trop Dis</i>. 2018;12(5):e0006527. doi:10.1371/journal.pntd.0006527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/29799869/pubmed" id="29799869" target="_blank">29799869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmBisome.2020.05">
<a name="AmBisome.2020.05"></a>AmBisome (amphotericin B [liposomal]) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amsden.2011">
<a name="Amsden.2011"></a>Amsden JR, Slain D. Antifungal dosing in obesity: a review of the literature. <i>Curr Fungal Infect Rep</i>. 2011;5:83-91. doi:10.1007/s12281-011-0049-7</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7747495">
<a name="7747495"></a>Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care? <i>West J Med</i>. 1995;162(4):313-317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/7747495/pubmed" id="7747495" target="_blank">7747495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352486">
<a name="29352486"></a>Andrew EC, Curtis N, Coghlan B, Cranswick N, Gwee A. Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations. <i>Br J Clin Pharmacol</i>. 2018;84(5):1006-1012. doi:10.1111/bcp.13521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/29352486/pubmed" id="29352486" target="_blank">29352486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941143">
<a name="27941143"></a>Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of Leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). <i>Clin Infect Dis</i>. 2016;63(12):1539-1557. doi:10.1093/cid/ciw742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/27941143/pubmed" id="27941143" target="_blank">27941143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900315">
<a name="30900315"></a>Baddley JW, Forrest GN; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13543. doi:10.1111/ctr.13543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/30900315/pubmed" id="30900315" target="_blank">30900315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15815047">
<a name="15815047"></a>Barron MA, Lay M, Madinger NE. Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin’s Disease who had undergone allogeneic hematopoietic stem cell transplantation. <i>J Clin Microbiol. </i>2005;43(4):2012-2014. doi:10.1128/JCM.43.4.2012-2014.2005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/15815047/pubmed" id="15815047" target="_blank">15815047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8566990">
<a name="8566990"></a>Bates CM, Carey PB, Hind CR. Anaphylaxis due to liposomal amphotericin (<i>AmBisome</i>). <i>Genitourin Med</i>. 1995;71(6):414. doi:10.1136/sti.71.6.414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/8566990/pubmed" id="8566990" target="_blank">8566990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11576359">
<a name="11576359"></a>Bates DW, Su L, Yu DT, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. <i>Kidney Int</i>. 2001;60(4):1452-1459. doi:10.1046/j.1523-1755.2001.00948.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11576359/pubmed" id="11576359" target="_blank">11576359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11850268">
<a name="11850268"></a>Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. <i>Antimicrob Agents Chemother</i>. 2002;46(3):828-833. doi:10.1128/aac.46.3.828-833.2002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11850268/pubmed" id="11850268" target="_blank">11850268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12615870">
<a name="12615870"></a>Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. <i>J Antimicrob Chemother</i>. 2003;51(3):671-681. doi:10.1093/jac/dkg139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/12615870/pubmed" id="12615870" target="_blank">12615870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26349818">
<a name="26349818"></a>Bicanic T, Bottomley C, Loyse A, et al. Toxicity of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated cryptococcal meningitis. <i>Antimicrob Agents Chemother</i>. 2015;59(12):7224-7231. doi:10.1128/AAC.01698-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26349818/pubmed" id="26349818" target="_blank">26349818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11261528">
<a name="11261528"></a>Bishara J, Weinberger M, Lin AY, Pitlik S. Amphotericin B--not so terrible. <i>Ann Pharmacother</i>. 2001;35(3):308-310. doi:10.1345/aph.10240<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11261528/pubmed" id="11261528" target="_blank">11261528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. American Academy of Pediatrics; 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23719882">
<a name="23719882"></a>Buckley MS, Anderson CS, Patel SA, Yerondopoulos MJ, Wicks LM, Martin MT. Apparent lack of cross-reactivity for infusion-related reactions between two forms of lipid-based amphotericin B. <i>Am J Health Syst Pharm</i>. 2013;70(12):1047-1051. doi:10.2146/ajhp120530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/23719882/pubmed" id="23719882" target="_blank">23719882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35147680">
<a name="35147680"></a>Burza S, Mahajan R, Kazmi S, et al. AmBisome monotherapy and combination AmBisome-miltefosine therapy for the treatment of visceral Leishmaniasis in patients coinfected with human immunodeficiency virus in India: a randomized open-label, parallel-arm, phase 3 trial. <i>Clin Infect Dis</i>. 2022;75(8):1423-1432. doi:10.1093/cid/ciac127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/35147680/pubmed" id="35147680" target="_blank">35147680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11560200">
<a name="11560200"></a>Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. <i>Pharmacotherapy</i>. 2001;21(9):1107-14. doi:10.1592/phco.21.13.1107.34613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11560200/pubmed" id="11560200" target="_blank">11560200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22571507">
<a name="22571507"></a>Caselli D, Cesaro S, Ziino O, et al. A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children. <i>Br J Haematol</i>. 2012;158(2):249-255. doi:10.1111/j.1365-2141.2012.09156.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/22571507/pubmed" id="22571507" target="_blank">22571507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10423056">
<a name="10423056"></a>Cesaro S, Calore E, Messina C, Zanesco L. Allergic reaction to the liposomal component of liposomal amphotericin B. <i>Support Care Cancer</i>. 1999;7(4):284-286. doi:10.1007/s005200050262<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/10423056/pubmed" id="10423056" target="_blank">10423056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention. Interim recommendations for diagnosis and management of fungal meningitis associated with epidural anesthesia administered in Matamoros, Mexico. Updated June 7, 2023. Accessed July 3, 2023. https://funguseducationhub.org/wp-content/uploads/2023/06/interim-recommendations-Matamoros-FM-outbreak-6_09_23.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2013">
<a name="CDC.2013"></a>Centers for Disease Control and Prevention. Interim treatment guidance for central nervous system (CNS) and parameningeal infections associated with injection of contaminated steroid products. October 23, 2013. <a href="https://www.cdc.gov/hai/outbreaks/clinicians/index.html" target="_blank">http://www.cdc.gov/hai/outbreaks/clinicians/index.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16354223">
<a name="16354223"></a>Cetin H, Yalaz M, Akisu M, Hilmioglu S, Metin D, Kultursay N. The efficacy of two different lipid-based amphotericin B in neonatal Candida septicemia. <i>Pediatr Int</i>. 2005;47(6):676-680. doi:10.1111/j.1442-200x.2005.02135.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/16354223/pubmed" id="16354223" target="_blank">16354223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18462107">
<a name="18462107"></a>Chapman SW, Dismukes WE, Proia LA, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008 Jun 15;46(12):1801-12. doi: 10.1086/588300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/18462107/pubmed" id="18462107" target="_blank">18462107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699664">
<a name="31699664"></a>Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium (ECMM/MSG-ERC). <i>Lancet Infect Dis</i>. 2019;19(12):e405‐e421. doi:10.1016/S1473-3099(19)30312-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/31699664/pubmed" id="31699664" target="_blank">31699664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10451192">
<a name="10451192"></a>Cronin JE, Barron RL. Anaphylaxis upon switching lipid-containing amphotericin B formulation. <i>Clin Infect Dis</i>. 1999;28(6):1342. doi:10.1086/517799<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/10451192/pubmed" id="10451192" target="_blank">10451192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30653490">
<a name="30653490"></a>Diro E, Blesson S, Edwards T, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral Leishmaniasis in HIV co-infected patients in Ethiopia. <i>PLoS Negl Trop Dis</i>. 2019;13(1):e0006988. doi:10.1371/journal.pntd.0006988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/30653490/pubmed" id="30653490" target="_blank">30653490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34325715">
<a name="34325715"></a>Drewett GP, Copaescu A, DeLuca J, Holmes NE, Trubiano JA. Asystolic cardiac arrest following liposomal amphotericin B infusion: anaphylaxis or compliment activation-related pseudoallergy? <i>Allergy Asthma Clin Immunol</i>. 2021;17(1):80. doi:10.1186/s13223-021-00582-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/34325715/pubmed" id="34325715" target="_blank">34325715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11801578">
<a name="11801578"></a>Dupont B. Overview of the lipid formulations of amphotericin B. <i>J Antimicrob Chemother.</i> 2002;49(suppl 1):31-36. doi:10.1093/jac/49.suppl_1.31<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11801578/pubmed" id="11801578" target="_blank">11801578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22581225">
<a name="22581225"></a>Dutta A, Palazzi DL. Risk factors of amphotericin B toxicity in the nonneonatal pediatric population. <i>Pediatr Infect Dis J</i>. 2012;31(9):910-914. doi:10.1097/INF.0b013e31825d649a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/22581225/pubmed" id="22581225" target="_blank">22581225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9243032">
<a name="9243032"></a>Edwards JE Jr, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. <i>Clin Infect Dis</i>. 1997;25(1):43-59. doi:10.1086/514504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/9243032/pubmed" id="9243032" target="_blank">9243032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10397206">
<a name="10397206"></a>Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. <i>Crit Care Med</i>. 1999;27(6):1066-1072. doi:10.1097/00003246-199906000-00019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/10397206/pubmed" id="10397206" target="_blank">10397206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35810338">
<a name="35810338"></a>Erat T, An I. Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B. <i>Dermatol Ther</i>. 2022;35(9):e15706. doi:10.1111/dth.15706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/35810338/pubmed" id="35810338" target="_blank">35810338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.<i> Intensive Care Med.</i> 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.doo">
<a name="expert.doo"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.dor">
<a name="expert.dor"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166189">
<a name="23166189"></a>Farmakiotis D, Tverdek FP, Kontoyiannis DP. The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B. <i>Clin Infect Dis</i>. 2013;56(5):701-703. doi:10.1093/cid/cis972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/23166189/pubmed" id="23166189" target="_blank">23166189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10839593">
<a name="10839593"></a>Fichtenbaum CJ, Zackin R, Rajicic N, Powderly WG, Wheat LJ, Zingman BS. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. <i>AIDS</i>. 2000;14(7):845-852. doi:10.1097/00002030-200005050-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/10839593/pubmed" id="10839593" target="_blank">10839593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17503015">
<a name="17503015"></a>Filioti J, Spiroglou K, Panteliadis CP, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. <i>Intensive Care Med</i>. 2007;33(7):1272-1283. doi:10.1007/s00134-007-0672-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/17503015/pubmed" id="17503015" target="_blank">17503015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-93. doi:10.1093/cid/cir073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16622909">
<a name="16622909"></a>Girois SB, Chapuis F, Decullier E, Revol BG. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. <i>Eur J Clin Microbiol Infect Dis</i>. 2006;25(2):138-149. doi:10.1007/s10096-005-0080-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/16622909/pubmed" id="16622909" target="_blank">16622909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al; Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy [published correction in <i>J Antimicrob Chemother</i>. 2012;67(5):1304]. <i>J Antimicrob Chemother</i>. 2012;67(2):269-289. doi:10.1093/jac/dkr450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33811813">
<a name="33811813"></a>Groll AH, Pana D, Lanternier F, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. <i>Lancet Oncol</i>. 2021;22(6):e254-e269. doi:10.1016/S1470-2045(20)30723-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/33811813/pubmed" id="33811813" target="_blank">33811813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34013538">
<a name="34013538"></a>Guarana M, Nouér SA, Nucci M. EQUAL Fusariosis score 2021: an European Confederation of Medical Mycology score derived from current guidelines to measure QUALity of the clinical management of invasive fusariosis. <i>Mycoses</i>. 2021;64(12):1542-1545. doi:10.1111/myc.13321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/34013538/pubmed" id="34013538" target="_blank">34013538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11382716">
<a name="11382716"></a>Gussak HM, Rahman S, Bastani B. Administration and clearance of amphotericin B during high-efficiency or high-efficiency/high-flux dialysis. <i>Am J Kidney Dis</i>. 2001;37(6):E45. doi:10.1053/ajkd.2001.24545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11382716/pubmed" id="11382716" target="_blank">11382716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26420570">
<a name="26420570"></a>Hagihara M, Yamagishi Y, Hirai J, et al. Drug-induced hypersensitivity syndrome by liposomal amphotericin-B: a case report. <i>BMC Res Notes</i>. 2015;8:510. doi:10.1186/s13104-015-1486-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26420570/pubmed" id="26420570" target="_blank">26420570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25222303">
<a name="25222303"></a>Hand EO, Ramanathan MR. Safety and tolerability of high-dose weekly liposomal amphotericin B antifungal prophylaxis. <i>Pediatr Infect Dis J</i>. 2014;33(8):835-836. doi:10.1097/INF.0000000000000335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/25222303/pubmed" id="25222303" target="_blank">25222303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577. doi:10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8722841">
<a name="8722841"></a>Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. <i>Clin Infect Dis</i>. 1996;22(suppl 2):S133-S144. doi:10.1093/clinids/22.supplement_2.s133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/8722841/pubmed" id="8722841" target="_blank">8722841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26553194">
<a name="26553194"></a>Hoetzenecker W, Nägeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding. <i>Semin Immunopathol</i>. 2016;38(1):75-86. doi:10.1007/s00281-015-0540-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26553194/pubmed" id="26553194" target="_blank">26553194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35320642">
<a name="35320642"></a>Jarvis JN, Lawrence DS, Meya DB, et al; Ambition Study Group. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. <i>N Engl J Med</i>. 2022;386(12):1109-1120. doi:10.1056/NEJMoa2111904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/35320642/pubmed" id="35320642" target="_blank">35320642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29945252">
<a name="29945252"></a>Jarvis JN, Leeme TB, Molefi M, et al. Short-course high-dose liposomal amphotericin B for human immunodeficiency virus-associated cryptococcal meningitis: a phase 2 randomized controlled trial. <i>Clin Infect Dis</i>. 2019;68(3):393-401. doi:10.1093/cid/ciy515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/29945252/pubmed" id="29945252" target="_blank">29945252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9758315">
<a name="9758315"></a>Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. <i>Pharmacotherapy</i>. 1998;18(5):1053-1061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/9758315/pubmed" id="9758315" target="_blank">9758315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13680398">
<a name="13680398"></a>Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. <i>Eur J Clin Microbiol Infect Dis</i>. 2003;22(10):603-607. doi:10.1007/s10096-003-0993-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/13680398/pubmed" id="13680398" target="_blank">13680398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968818">
<a name="17968818"></a>Kauffman CA, Bustamante B, Chapman SW, Pappas PG; Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(10):1255-1265. doi:10.1086/522765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/17968818/pubmed" id="17968818" target="_blank">17968818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.1">
<a name="Kauffman.1"></a>Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23083312">
<a name="23083312"></a>Kauffman CA, Pappas PG, Patterson TF. Fungal infections associated with contaminated methylprednisolone injections. <i>N Engl J Med</i>. 2013;368(26):2495-500. doi:10.1056/NEJMra1212617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/23083312/pubmed" id="23083312" target="_blank">23083312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9827262">
<a name="9827262"></a>King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. <i>Clin Infect Dis</i>. 1998;27(5):1151-1160. doi: 10.1086/514977<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/9827262/pubmed" id="9827262" target="_blank">9827262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28945677">
<a name="28945677"></a>Kobayashi R, Keino D, Hori D, et al. Analysis of hypokalemia as a side effect of liposomal amphotericin in pediatric patients. <i>Pediatr Infect Dis J</i>. 2018;37(5):447-450. doi:10.1097/INF.0000000000001802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/28945677/pubmed" id="28945677" target="_blank">28945677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7915365">
<a name="7915365"></a>Laing RB, Milne LJ, Leen CL, Malcolm GP, Steers AJ. Anaphylactic reactions to liposomal amphotericin. <i>Lancet</i>. 1994;344(8923):682. doi:10.1016/s0140-6736(94)92116-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/7915365/pubmed" id="7915365" target="_blank">7915365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26316385">
<a name="26316385"></a>Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. <i>J Antimicrob Chemother</i>. 2015;70(11):3116‐3123. doi:10.1093/jac/dkv236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26316385/pubmed" id="26316385" target="_blank">26316385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9792309">
<a name="9792309"></a>Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. <i>Br J Haematol</i>. 1998;103(1):205-212. doi:10.1046/j.1365-2141.1998.00944.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/9792309/pubmed" id="9792309" target="_blank">9792309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23931455">
<a name="23931455"></a>Loo AS, Muhsin SA, Walsh TJ. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. <i>Expert Opin Drug Saf</i>. 2013;12(6):881-895. doi:10.1517/14740338.2013.827168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/23931455/pubmed" id="23931455" target="_blank">23931455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14692429">
<a name="14692429"></a>Lowery MM, Greenberger PA. Amphotericin-induced stridor: a review of stridor, amphotericin preparations, and their immunoregulatory effects. <i>Ann Allergy Asthma Immunol</i>. 2003;91(5):460-466. doi:10.1016/S1081-1206(10)61514-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/14692429/pubmed" id="14692429" target="_blank">14692429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1379913">
<a name="1379913"></a>Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. <i>Drugs</i>. 1992;44(1):9-35. doi:10.2165/00003495-199244010-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/1379913/pubmed" id="1379913" target="_blank">1379913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11847833">
<a name="11847833"></a>Mactal-Haaf C, Hoffman M, Kuchta A. Use of anti-infective agents during lactation, Part 3: Antivirals, antifungals, and urinary antiseptics. <i>J Hum Lact</i>. 2001;17(2):160-166. doi:10.1177/089033440101700214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11847833/pubmed" id="11847833" target="_blank">11847833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26129756">
<a name="26129756"></a>Mahajan R, Das P, Isaakidis P, et al. Combination treatment for visceral Leishmaniasis patients coinfected with human immunodeficiency virus in India. <i>Clin Infect Dis</i>. 2015;61(8):1255-1262. doi:10.1093/cid/civ530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26129756/pubmed" id="26129756" target="_blank">26129756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24922279">
<a name="24922279"></a>Marking U, den Boer M, Das AK, et al. Hypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report. <i>PLoS Negl Trop Dis</i>. 2014;8(6):e2864. doi:10.1371/journal.pntd.0002864<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/24922279/pubmed" id="24922279" target="_blank">24922279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Matsuoka.2011">
<a name="Matsuoka.2011"></a>Matsuoka T, Usami E, Yoshimura T, Takada H, Yasuda T. (2011) Risk factors contributing to occurrence of hypokalemia after liposomal-amphotericin B administration. <i>Iryo Yakugaku (Japanese J Pharm Heal Care Sci).</i> 2011;37:487-493.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30924967">
<a name="30924967"></a>Miller R, Assi M; AST Infectious Diseases Community of Practice. Endemic fungal infections in solid organ transplant recipients-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13553. doi:10.1111/ctr.13553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/30924967/pubmed" id="30924967" target="_blank">30924967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33549818">
<a name="33549818"></a>Milosevits G, Mészáros T, Őrfi E, et al. Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion. <i>Nanomedicine</i>. 2021;34:102366. doi:10.1016/j.nano.2021.102366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/33549818/pubmed" id="33549818" target="_blank">33549818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22491505">
<a name="22491505"></a>Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. <i>Clin Infect Dis</i>. 2012;54(12):1774-1777. doi:10.1093/cid/cis290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/22491505/pubmed" id="22491505" target="_blank">22491505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12490683">
<a name="12490683"></a>Mora-Duarte J, Betts R, Rotstein C, et al; Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. <i>N Engl J Med</i>. 2002;347(25):2020-2029. doi:10.1056/NEJMoa021585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/12490683/pubmed" id="12490683" target="_blank">12490683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21976565">
<a name="21976565"></a>Mukhtar M, Aboud M, Kheir M, et al. First report on Ambisome-associated allergic reaction in two Sudanese leishmaniasis patients. <i>Am J Trop Med Hyg</i>. 2011;85(4):644-6445. doi:10.4269/ajtmh.2011.10-0511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/21976565/pubmed" id="21976565" target="_blank">21976565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25139411">
<a name="25139411"></a>Nath P, Basher A, Harada M, et al. Immediate hypersensitivity reaction following liposomal amphotericin-B (<i>AmBisome</i>) infusion. <i>Trop Doct</i>. 2014;44(4):241-242. doi:10.1177/0049475514543655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/25139411/pubmed" id="25139411" target="_blank">25139411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nemecek.2019">
<a name="Nemecek.2019"></a>Nemecek BD, Hammond DA, eds. <i>Demystifying Drug Dosing in Renal Dysfunction. American Society of Health-System Pharmacists</i>; 2019<i>.</i>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34716724">
<a name="34716724"></a>Noyman Y, Levi A, Ben Amitai D, et al. Treating pediatric cutaneous <i>Leishmania tropica</i> with systemic liposomal amphotericin B: a retrospective, single-center study. <i>Dermatol Ther</i>. 2022;35(1):e15185. doi:10.1111/dth.15185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/34716724/pubmed" id="34716724" target="_blank">34716724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nucci.1">
<a name="Nucci.1"></a>Nucci MN, Anaissie E. Treatment and prevention of Fusarium infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24118322">
<a name="24118322"></a>Nucci M, Marr KA, Vehreschild MJ, et al. Improvement in the outcome of invasive fusariosis in the last decade. <i>Clin Microbiol Infect</i>. 2014;20(6):580-585. doi:10.1111/1469-0691.12409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/24118322/pubmed" id="24118322" target="_blank">24118322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12872351">
<a name="12872351"></a>Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. <i>Cancer</i>. 2003;98(2):315-319. doi:10.1002/cncr.11510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/12872351/pubmed" id="12872351" target="_blank">12872351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33179180">
<a name="33179180"></a>Obata Y, Takazono T, Tashiro M, et al. The clinical usage of liposomal amphotericin B in patients receiving renal replacement therapy in Japan: a nationwide observational study. <i>Clin Exp Nephrol</i>. 2021;25(3):279-287. doi:10.1007/s10157-020-01989-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/33179180/pubmed" id="33179180" target="_blank">33179180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15003897">
<a name="15003897"></a>Pagano L, Offidani M, Fianchi L, et al; GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Infection Program. Mucormycosis in hematologic patients. <i>Haematologica</i>. 2004 ;89(2):207-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/15003897/pubmed" id="15003897" target="_blank">15003897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679628">
<a name="26679628"></a>Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America (IDSA). <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi:10.1093/cid/civ933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26679628/pubmed" id="26679628" target="_blank">26679628</a>]</span>
<span class="doi">10.1093/cid/civ933</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9868423">
<a name="9868423"></a>Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. <i>Mayo Clin Proc</i>. 1998;73(12):1205-1225. doi:10.4065/73.12.1205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/9868423/pubmed" id="9868423" target="_blank">9868423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27365388">
<a name="27365388"></a>Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. Accessed August 8, 2016. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/27365388/pubmed" id="27365388" target="_blank">27365388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27481947">
<a name="27481947"></a>Patterson TF, Thompson GR 3rd, Denning DW, et al. Executive summary: Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2016;63(4):433-442. doi:10.1093/cid/ciw444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/27481947/pubmed" id="27481947" target="_blank">27481947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047480">
<a name="20047480"></a>Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. <i>Clin Infect Dis</i>. 2010;50(3):291-322. doi:10.1086/649858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/20047480/pubmed" id="20047480" target="_blank">20047480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30809394">
<a name="30809394"></a>Personett HA, Kayhart BM, Barreto EF, et al. Renal recovery following liposomal amphotericin B-induced nephrotoxicity. <i>Int J Nephrol</i>. 2019;2019:8629891. doi:10.1155/2019/8629891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/30809394/pubmed" id="30809394" target="_blank">30809394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25204341">
<a name="25204341"></a>Pilmis B, Jullien V, Sobel J, et al. Lecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: an updated review. <i>J Antimicrob Chemother</i>. 2015;70(1):14-22. doi:10.1093/jac/dku355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/25204341/pubmed" id="25204341" target="_blank">25204341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9332329">
<a name="9332329"></a>Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. <i>Br J Haematol</i>. 1997;98(3):711-7118. doi:10.1046/j.1365-2141.1997.2473063.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/9332329/pubmed" id="9332329" target="_blank">9332329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18679151">
<a name="18679151"></a>Queiroz-Telles F, Berezin E, Leverger G, et al; Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. <i>Pediatr Infect Dis J</i>. 2008;27(9):820-826. doi:10.1097/INF.0b013e31817275e6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/18679151/pubmed" id="18679151" target="_blank">18679151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7935701">
<a name="7935701"></a>Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. <i>N Engl J Med</i>. 1994;331(20):1325-1330. doi:10.1056/NEJM199411173312001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/7935701/pubmed" id="7935701" target="_blank">7935701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12746765">
<a name="12746765"></a>Rex JH, Pappas PG, Karchmer AW, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. <i>Clin Infect Dis</i>. 2003;36(10):1221-1228. doi:10.1086/374850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/12746765/pubmed" id="12746765" target="_blank">12746765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10770728">
<a name="10770728"></a>Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2000;30(4):662-678. doi:10.1086/313749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/10770728/pubmed" id="10770728" target="_blank">10770728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7703925">
<a name="7703925"></a>Ringdén O, Andström E, Remberger M, Svahn BM, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. <i>Bone Marrow Transplant</i>. 1994;14(suppl 5):S10-S14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/7703925/pubmed" id="7703925" target="_blank">7703925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26014956">
<a name="26014956"></a>Rocha PN, Kobayashi CD, de Carvalho Almeida L, de Oliveira Dos Reis C, Santos BM, Glesby MJ. Incidence, predictors, and impact on hospital mortality of amphotericin B nephrotoxicity defined using newer acute kidney injury diagnostic criteria. <i>Antimicrob Agents Chemother</i>. 2015;59(8):4759-4769. doi:10.1128/AAC.00525-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26014956/pubmed" id="26014956" target="_blank">26014956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12746764">
<a name="12746764"></a>Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. <i>Clin Infect Dis</i>. 2003;36(10):1213-1220. doi:10.1086/374553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/12746764/pubmed" id="12746764" target="_blank">12746764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16918064">
<a name="16918064"></a>Rokicka M. AmBisome treatment of fungal sinusitis in severe immunocompromised patient with acute lymphoblastic leukemia relapsed after autologous peripheral blood transplantation. <i>Acta Biomed</i>. 2006;77(suppl 2):26-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/16918064/pubmed" id="16918064" target="_blank">16918064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8997484">
<a name="8997484"></a>Sacks GS, Cleary JD. Nutritional impact of lipid-associated amphotericin B formulations. <i>Ann Pharmacother</i>. 1997;31(1):121-122. doi:10.1177/106002809703100124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/8997484/pubmed" id="8997484" target="_blank">8997484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20616663">
<a name="20616663"></a>Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. <i>Medicine (Baltimore)</i>. 2010;89(4):236-244. doi:10.1097/MD.0b013e3181e9441b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/20616663/pubmed" id="20616663" target="_blank">20616663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7579079">
<a name="7579079"></a>Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. <i>J Am Soc Nephrol</i>. 1995;6(2):154-164. doi:10.1681/ASN.V62154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/7579079/pubmed" id="7579079" target="_blank">7579079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34696915">
<a name="34696915"></a>Scardina T, Fawcett AJ, Patel SJ. Amphotericin-associated infusion-related reactions: A narrative review of pre-medications. <i>Clin Ther</i>. 2021;43(10):1689-1704. doi:10.1016/j.clinthera.2021.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/34696915/pubmed" id="34696915" target="_blank">34696915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9734666">
<a name="9734666"></a>Schneider P, Klein RM, Dietze L, Söhngen D, Leschke M, Heyll A. Anaphylactic reaction to liposomal amphotericin (<i>AmBisome</i>). <i>Br J Haematol</i>. 1998;102(4):1108-1109. doi:10.1046/j.1365-2141.1998.0952a.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/9734666/pubmed" id="9734666" target="_blank">9734666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27743834">
<a name="27743834"></a>Shadur B, Trahair TN, O'Brien T, Russell SJ, Ziegler JB. Desensitisation to liposomal amphotericin <i>B. J Allergy Clin Immunol Pract</i>. 2017;5(1):181-183. doi:10.1016/j.jaip.2016.08.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/27743834/pubmed" id="27743834" target="_blank">27743834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10221369">
<a name="10221369"></a>Slain D. Lipid-based amphotericin B for the treatment of fungal infections. <i>Pharmacotherapy</i>. 1999;19(3):306-323. doi:10.1592/phco.19.4.306.30934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/10221369/pubmed" id="10221369" target="_blank">10221369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11428998">
<a name="11428998"></a>Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. <i>Transpl Infect Dis</i>. 1999;1(4):273-283. doi:10.1034/j.1399-3062.1999.010406.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11428998/pubmed" id="11428998" target="_blank">11428998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18582201">
<a name="18582201"></a>Tunkel AR, Glaser CA, Bloch KC, et al; Infectious Diseases Society of America. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;47(3):303-327. doi:10.1086/589747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/18582201/pubmed" id="18582201" target="_blank">18582201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24669255">
<a name="24669255"></a>Usami E, Kimura M, Kanematsu T, et al. Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B. <i>Exp Ther Med</i>. 2014;7(4):941-946. doi:10.3892/etm.2014.1534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/24669255/pubmed" id="24669255" target="_blank">24669255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HIV.7">
<a name="HIV.7"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new?view=full" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new?view=full</a>. Updated September 25, 2023. Accessed November 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HIV.2">
<a name="HIV.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed October 5, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HIV.12">
<a name="HIV.12"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new</a>. Updated September 14, 2023. Accessed November 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12196074">
<a name="12196074"></a>Vaidya SJ, Seydel C, Patel SR, Ortin M. Anaphylactic reaction to liposomal amphotericin B. <i>Ann Pharmacother</i>. 2002;36(9):1480-1481. doi:10.1345/aph.1C001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/12196074/pubmed" id="12196074" target="_blank">12196074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vazquez.1">
<a name="Vazquez.1"></a>Vazquez JA. Management of candidemia and invasive candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed July 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23774005">
<a name="23774005"></a>Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. <i>Diagn Microbiol Infect Dis</i>. 2013;76(3):361-367. doi:10.1016/j.diagmicrobio.2013.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/23774005/pubmed" id="23774005" target="_blank">23774005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10072411">
<a name="10072411"></a>Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. <i>N Engl J Med</i>. 1999;340(10):764-771. doi:10.1056/NEJM199903113401004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/10072411/pubmed" id="10072411" target="_blank">10072411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31588493">
<a name="31588493"></a>Wasmann RE, Smit C, van Dongen EPH, et al. Fixed dosing of liposomal amphotericin B in morbidly obese individuals. <i>Clin Infect Dis</i>. 2020;70(10):2213-2215. doi:10.1093/cid/ciz885<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/31588493/pubmed" id="31588493" target="_blank">31588493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10669191">
<a name="10669191"></a>Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. <i>Ann Pharmacother</i>. 2000;34(1):94-97. doi:10.1345/aph.19127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/10669191/pubmed" id="10669191" target="_blank">10669191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17806045">
<a name="17806045"></a>Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(7):807‐825. doi:10.1086/521259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/17806045/pubmed" id="17806045" target="_blank">17806045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11073745">
<a name="11073745"></a>Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A; L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. <i>Clin Infect Dis</i>. 2000;31(5):1155-1163. doi:10.1086/317451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11073745/pubmed" id="11073745" target="_blank">11073745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Geneva: World Health Organization; 2022. https://www.who.int/publications/i/item/9789240052178. Accessed October 5, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization. WHO guidelines for the treatment of visceral Leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. Geneva: World Health Organization; 2022. https://www.who.int/publications/i/item/9789240048294. Accessed September 26, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33239137">
<a name="33239137"></a>Yokota T, Yoshikawa N, Arimori K, Ikeda R. Retrospective analysis of risk factors for liposomal amphotericin B-associated nephrotoxicity. <i>Pharmazie</i>. 2020;75(11):599-601. doi:10.1691/ph.2020.0731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/33239137/pubmed" id="33239137" target="_blank">33239137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29136631">
<a name="29136631"></a>Zhang B, Li Q, Shi C, Zhang X. Drug-induced pseudoallergy: A review of the causes and mechanisms. <i>Pharmacology</i>. 2018;101(1-2):104-110. doi:10.1159/000479878<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/29136631/pubmed" id="29136631" target="_blank">29136631</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12669 Version 275.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
